Towards combination HIV prevention for injection drug users: Addressing addictophobia, apathy and inattention

Current Opinion in HIV and AIDS

Volumn 7, Issue 4, 2012, Pages 320-325

  Strathdee, Steffanie A ^a   Shoptaw, Steven ^b   Dyer, Typhanye Penniman ^c   Quan, Vu Minh ^d   Aramrattana, Apinun ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

drug abuse treatment; HIV; injection drug use; needle and syringe exchange programs; pre exposure prophylaxis

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; METHAMPHETAMINE; OPIATE;

ADDICTOPHOBIA; ANTIVIRAL THERAPY; APATHY; ATTENTION DISTURBANCE; CHEMOPROPHYLAXIS; CLINICAL PROTOCOL; CLINICAL RESEARCH; DRUG DEPENDENCE; DRUG EXPOSURE; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH PROMOTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; METHAMPHETAMINE DEPENDENCE; MORBIDITY; MORTALITY; NEEDLE AND SYRINGE PROGRAM; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PATIENT COUNSELING; PHOBIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VOLUNTARY COUNSELING AND TESTING;

ANTI-RETROVIRAL AGENTS; BEHAVIOR THERAPY; CHEMOPREVENTION; COMMUNICABLE DISEASE CONTROL; HEPATITIS C; HIV INFECTIONS; HUMANS; NEEDLE-EXCHANGE PROGRAMS; OPIATE SUBSTITUTION TREATMENT; SUBSTANCE ABUSE, INTRAVENOUS; TUBERCULOSIS;

EID: 84862565059     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32835369ad     Document Type: Review

References (40)

1. Cohen J. Breakthrough of the year: HIV treatment as prevention. Science 2011; 334:1628.
2. Grant RM. Antiretroviral agents used by HIV-uninfected persons for prevention: pre-and post-exposure prophylaxis. Clin Infect Dis 2010; 50 (SUPPL. 3): S96.
3. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Morbidity and Mortality Weekly Report 1998; 47:39-82.
4. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. Update: Provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. Morb Mortal Wkly Rep 1996; 45:468-472.
5. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997; 337:1485-1490. (Pubitemid 27495773)
6. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the US Department of Health and Human Services. MMWR Recomm Rep 2005; 54:1-20.
7. Lurie P, Miller S, Hecht F, et al. Postexposure prophylaxis after nonoccupational HIV exposure. J Am Med Assoc 1998; 280:1769.
8. Degenhardt L, Mathers B, Vickerman P, et al. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 2010; 376:285-301.
9. Strathdee SA, Hallett TB, Bobrova N, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet 2010; 376:268-284.
10. Kurth AE, Celum C, Baeten JM, et al. Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep 2011; 1-11.
11. Burns DN, Dieffenbach CW, Vermund SH. Rethinking prevention of HIV type 1 infection. Clin Infect Dis 2010; 51:725.
12. Buchbinder SP, Liu A. Preexposure prophylaxis and the promise of combination prevention approaches. AIDS Behav 2011; 1-8.
13. Krakower D, Mayer KH. Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications. Curr HIV/AIDS Rep 2011; 1-8.
14. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014-1024.
15. Centers for Disease Control and Prevention. Recommendations on use of new treatment pption for latent TB infection. Morbidity & Mortality Weekly Report 2011; 60:1650-1653.
16. Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010; 375:1014-1028.
17. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. Geneva; 2010.
18. Quan VM, Minh NL, Ha TV, et al. Mortality and HIV transmission among male Vietnamese injection drug users. Addiction 2011; 106:583-589.
19. Malta M, Bastos FI, da Silva CMFP, et al. Differential survival benefit of universal HAART access in Brazil: a nation-wide comparison of injecting drug users versus men who have sex with men. J Acquir Immune Defic Syndr 2009; 52:629.
20. Blansfield H. Addictophobia. Connect Med 1991; 55:361.
21. Human Rights WatC.H. Where darkness knows no limits: incarceration, ill-treatment and forced labor as drug rehabilitation in China. 2010 [cited 2011 December 21]; Available from: http://www.hrw.org.
22. Vongchak T, Kawichai S, Sherman S, et al. The influence of Thailands 2003 war on drugs policy on self-reported drug use among injection drug users in Chiang Mai, Thailand. Int J Drug Policy 2005; 16:115-121. (Pubitemid 40348751)
23. Kerr T, Kiatying-Angsulee N, Fairbairn N, et al. High rate of midazolam injection among drug users in Bangkok, Thailand. Harm Reduction J 2010a; 7.
24. Global SMART Programme, UNODC (2011). Amphetamine and ecstasy: 2011 global ATS assessment. United Nations Office on Drugs and Crime, Vienna, p. 12.
25. Thomas L. Reinstating the federal ban on syringe exchange funding is murderous. 2011 [cited 2012 January 3]; Available from: http://www.alternet. org/drugs/153478/reinstating-the-federal-ban-on-syringe-exchange-funding-is- murderous.
26. Montaner JSG, Wood E, Kerr T, et al. Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes. J Acquir Immune Defic Syndr 2010; 55:S5.
27. MilloyMJ, Kerr T, Bangsberg DR, et al. Homelessness as a structural barrier to effective antiretroviral therapy among HIV-seropositive illicit drug users in a Canadian setting. AIDS Patient Care and STDs 2012; 26:60-67.
28. World Health Organization. UNAIDS: Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. World Health Organization; 2009.
29. Hillis SD, Zapata L, Robbins CL, et al. HIV seroprevalence among orphaned and homeless youth: no place like home. AIDS 2012; 26:105.
30. Mastro TD, Cunningham J, Medrano T, van Dam J. Youth and HIV: the intersection of homelessness, orphaned status, injection drug use and sexual risk. AIDS 2012; 26:111.
31. DeJarlais DC. The 1993 Okey Memorial Lecture: cross-national studies of AIDS among injecting drug users. Addiction 1994; 89:383-392.
32. Strathdee SA, Lozada R, Martinez G, et al. Social and structural factors associated with HIV infection among female sex workers who inject drugs in the Mexico-US border region. PLoS One 2011; 6:e19048.
33. Brown QL, Cavanaugh CE, Penniman TV, Latimer WW. The impact of homelessness on recent sex trade among pregnant women in drug treatment. J Subs Use 2011; 1-7.
34. Cavanaugh CE, Latimer WW. Recent sex trade and injection drug use among pregnant opiate and cocaine dependent women in treatment: the significance of psychiatric comorbidity. Addict Disord Their Treatment 2010; 9:32.
35. El-Bassel N, et al. Curr Opin HIV/AIDS. 2012.
36. Quan VM, Aramrattana A, Vongchak T, et al. Mortality among injection drug users in northern Thailand: a prospective cohort study. J Addict Med 2010; 4:217.
37. Crawford ND, Vlahov D. Progress in HIV reduction and prevention among injection and noninjection drug users. J Acquir Immune Defic Syndr 2010; 55:S84.
38. Kim SC, Becker S, Dieffenbach C, et al. Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Soc 2010; 13:24.
39. Plomp HN, Hek HVD, Ader HJ. The Amsterdam methadone dispensing circuit: genesis and effectiveness of a public health model for local drug policy. Addiction 1996; 91:711-722.
40. Cheever LW, Kresina TF, Cajina A, Lubran R. A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care. J Acquir Immune Defic Syndr 2011; 56:S3.